Related references
Note: Only part of the references are listed.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefania Garcia-Guerrero et al.
LEUKEMIA (2021)
Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
Michelle Kinder et al.
HAEMATOLOGICA (2021)
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mikhael et al.
BLOOD CANCER JOURNAL (2021)
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
Kristine A. Frerichs et al.
CANCERS (2021)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2020)
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
Meisam Naeimi Kararoudi et al.
BLOOD (2020)
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
Daisuke Ogiya et al.
BLOOD (2020)
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
Christie P. M. Verkleij et al.
CANCERS (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
Ajay K. Nooka et al.
CANCER (2019)
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M. Boyle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)
Nizar Bahlis et al.
BLOOD (2019)
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Marina Silvia Parisi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab
Ryan Bjordahl et al.
BLOOD (2019)
CD20-selective inhibition of CD47-SIRP alpha don't eat me signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Peter E. van Bommel et al.
ONCOIMMUNOLOGY (2018)
Immunomodulatory effects of CD38-targeting antibodies
Niels W. C. J. van de Donk
IMMUNOLOGY LETTERS (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
Rimke Oostvogels et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models
Natalie A. Bezman et al.
CANCER RESEARCH (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients
Paola Neri et al.
BLOOD (2018)
Iberdomide (CC-220) Has Synergistic Anti Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro
Michael Amatangelo et al.
BLOOD (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R. Hajek et al.
LEUKEMIA (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
Estefania Garcia-Guerrero et al.
BLOOD (2017)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
Sanne J. de Haart et al.
HAEMATOLOGICA (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
Sanne J. de Haart et al.
HAEMATOLOGICA (2016)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof et al.
CLINICAL CANCER RESEARCH (2015)
Share Paper
